Literature DB >> 24384537

Impact of meningococcal C conjugate vaccination campaign in Emilia-Romagna, Italy.

Maria Grazia Pascucci1, Valentina Di Gregori2, Gabriella Frasca1, Paola Rucci2, Alba Carola Finarelli1, Laura Moschella1, Bianca Maria Borrini1, Francesca Cavrini3, Giovanna Liguori3, Vittorio Sambri4, Paolo Bonanni5, Maria Pia Fantini2.   

Abstract

The incidence of reported meningococcal disease in Italy is among the lowest in Europe. The trend of the disease was increasing up to 2005 and then declined after the gradual introduction of a universal Men C vaccination program in 17/21 Italian regions. Since 2006, in Emilia-Romagna region vaccination against Neisseria meningitidis serogroup C was actively offered free of charge in a single dose to the age groups 12-15 months and 14-15 years, in addition to people with defined epidemiological risk. Our aim was to measure the impact of vaccination on the incidence of meningococcal disease caused by different serogroups among the population of Emilia Romagna Region, Northern Italy (approximately 4.5 million inhabitants) subdivided by age. Using surveillance data, we computed the incidence rates of Neisseria meninigitidis related invasive disease per 100.000 inhabitants for the years 2000 to 2012. In addition, the percentage change in incidence and the mortality rates were calculated. Results indicate a 70.1% decrease in the incidence of meningococcus C-related invasive disease after the introduction of MenC universal vaccination. No case of serogroup C related infection was observed since 2006 in children aged 1-4 years. These findings suggest that the single-dose vaccination strategy against serogroup C N.meningitidis targeted to the age groups 12-15 months and 14-15 years was effective in the Emilia-Romagna population. However, the occurrence of two cases of meningiditis in a 5-month child and in a 9-years child suggests caution and careful consideration in surveillance for the next years.

Entities:  

Keywords:  meningococcal disease; serogroups; surveillance; vaccination campaign; vaccination coverage; vaccination strategies

Mesh:

Substances:

Year:  2013        PMID: 24384537      PMCID: PMC4130270          DOI: 10.4161/hv.27597

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  20 in total

Review 1.  Impact of meningococcal C conjugate vaccine in the UK.

Authors:  P Balmer; R Borrow; E Miller
Journal:  J Med Microbiol       Date:  2002-09       Impact factor: 2.472

2.  Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands.

Authors:  Sabine C de Greeff; Hester E de Melker; Lodewijk Spanjaard; Leo M Schouls; Arie van Derende
Journal:  Pediatr Infect Dis J       Date:  2006-01       Impact factor: 2.129

3.  Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity.

Authors:  Helen Campbell; Nick Andrews; Ray Borrow; Caroline Trotter; Elizabeth Miller
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

4.  Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

Authors:  P Richmond; R Borrow; D Goldblatt; J Findlow; S Martin; R Morris; K Cartwright; E Miller
Journal:  J Infect Dis       Date:  2000-11-14       Impact factor: 5.226

5.  Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Authors:  Andrew J Pollard; Kirsten P Perrett; Peter C Beverley
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

6.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.

Authors:  Caroline L Trotter; Nick J Andrews; Edward B Kaczmarski; Elizabeth Miller; Mary E Ramsay
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

Review 7.  Update on universal childhood immunizations.

Authors:  Jean Hamlin; Selvi Senthilnathan; Henry H Bernstein
Journal:  Curr Opin Pediatr       Date:  2008-08       Impact factor: 2.856

8.  Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.

Authors:  M D Snape; D F Kelly; S Lewis; C Banner; L Kibwana; C E Moore; L Diggle; T John; L M Yu; R Borrow; A Borkowski; C Nau; A J Pollard
Journal:  BMJ       Date:  2008-06-05

9.  Changes in the evolution of meningococcal disease, 2001-2008, Catalonia (Spain).

Authors:  Ana I Martínez; Angela Dominguez; Manuel Oviedo; Sofia Minguell; Josep M Jansa; Gemma Codina; Julio A Vazquez
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

Review 10.  Meningococcal carriage and disease--population biology and evolution.

Authors:  Dominique A Caugant; Martin C J Maiden
Journal:  Vaccine       Date:  2009-05-21       Impact factor: 3.641

View more
  4 in total

1.  Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.

Authors:  Chiara de Waure; Alessandro Miglietta; Darko Nedovic; Giovanna Mereu; Walter Ricciardi
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

2.  Estimation of the Impact of Meningococcal Serogroup C Universal Vaccination in Italy and Suggestions for the Multicomponent Serogroup B Vaccine Introduction.

Authors:  Domenico Martinelli; Francesca Fortunato; Maria Giovanna Cappelli; Vanessa Cozza; Maria Chironna; Rosa Prato
Journal:  J Immunol Res       Date:  2015-08-17       Impact factor: 4.818

3.  Impact and effectiveness of meningococcal vaccines: a review.

Authors:  Lucia Helena De Oliveira; Barbara Jauregui; Ana Flavia Carvalho; Norberto Giglio
Journal:  Rev Panam Salud Publica       Date:  2017-12-20

4.  Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs.

Authors:  Myint Tin Tin Htar; Sally Jackson; Paul Balmer; Lidia Cristina Serra; Andrew Vyse; Mary Slack; Margarita Riera-Montes; David L Swerdlow; Jamie Findlow
Journal:  BMC Public Health       Date:  2020-12-09       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.